Abstract
BackgroundFor patients with R/M HNSCC, current treatments are palliative with anti-PD-1 checkpoint inhibitor +/- platinum and 5-fluorouracil chemotherapy for first-line followed by taxanes, methotrexate, and cetuximab as later-line options. The...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have